The human poliovirus receptor consists of three extracellular immunoglobulinlike domains, a transmembrane domain, and an intracytoplasmic domain. The amino-terminal variable-type domain (V domain) of the human poliovirus receptor is necessary and sufficient for its function as a viral receptor (H.-C. Selinka, A. Zibert, and E. Wimmer, Proc. NatI. Acad. Sci. USA 88:3598-3602, 1991 (Fig. 1A) , when attached to the transmembrane and cytoplasmic domains of CD4, resulted in a functional receptor for poliovirus. Figure 1B outlines the organization of the three receptor constructs (PVRdl/CD4, PVR, and PVRdl) used in this study. Construction of expression plasmids pTMPVR, encoding the wild-type poliovirus receptor (PVR; 417 amino acids), and pTMdl, encoding a one-domain receptor (PVRdl; 260 amino acids), was described recently (22, 27) . Plasmid pPVRdl/CD4, encoding a hybrid PVR/CD4 receptor of 398 amino acids, was constructed from pTMPVR and pSV7d, the latter containing CD4 cDNA (provided by Dan Littman). Plasmid pTMPVR contains two silent mutations at nucleotide 663 and nucleotide 946 harboring restriction sites for NheI and HpaI at the C-terminal ends of domain 1 (NheI) and domain 2 (HpaI), respectively. These mutations allowed us to join the immunoglobulinlike domains of PVR and CD4 at the desired boundaries. Plasmid pTMPVR was digested with NheI and HpaI, and a NheI-HpaI fragment of pSV7d was inserted, leading to an in-frame fusion of the coding sequence of domain 1 of PVR (amino acids 1 to 143) to the sequence coding for amino acids 214 to 468 of CD4 (Fig. 1A) .
The human poliovirus receptor consists of three extracellular immunoglobulinlike domains, a transmembrane domain, and an intracytoplasmic domain. The amino-terminal variable-type domain (V domain) of the human poliovirus receptor is necessary and sufficient for its function as a viral receptor (H.-C. Selinka, A. Zibert, and E. Wimmer, Proc. NatI. Acad. Sci. USA 88: [3598] [3599] [3600] [3601] [3602] 1991) . In this paper, data are presented showing that transfer of the putative poliovirus receptor-binding domain to a truncated receptor for the human immunodeficiency virus results in a functional receptor for poliovirus. After expression in mouse cells, this chimeric protein confers susceptibility to poliovirus. Thus, unlike human immunodeficiency virus, poliovirus can enter mouse cells by way of a truncated CD4 receptor if the specific binding domain for poliovirus is provided.
Virus receptors are structures on the cell surface that mediate virus infection of the cell through attachment and internalization. A human poliovirus receptor (PVR) for all three serotypes of poliovirus has recently been identified by using a genetic approach (17, 18) . PVR is a new member of the immunoglobulin superfamily with three extracellular domains in the order V-C2-C2, followed by a transmembrane region and a cytoplasmic tail. In the nonglycosylated form, PVR is a protein of 43 or 45 kDa, depending on the nature of the C terminus (18) . After modification of some or all of its glycosylation sites, a glycoprotein of about 67 kDa could be demonstrated by Western blot (immunoblot) analysis of human tissues (4) and cultured cells (27) , by expression in rabbit reticulocyte lysates, or by vaccinia virus expression in vivo (27) . A similar protein of about 67 kDa was found in a baculovirus expression system (9) . Recently, several deletion mutants of PVR have been described (5, 10, 22) . Their properties suggest that the primary binding site for poliovirus resides in domain 1 (V domain) of PVR. We have mapped the major poliovirus-binding region to the N-terminal domain of PVR by means of a hybrid clone encoding a chimera of PVR and intercellular adhesion molecule 1 (ICAM-1) (22) Figure 1B outlines the organization of the three receptor constructs (PVRdl/CD4, PVR, and PVRdl) used in this study. Construction of expression plasmids pTMPVR, encoding the wild-type poliovirus receptor (PVR; 417 amino acids), and pTMdl, encoding a one-domain receptor (PVRdl; 260 amino acids), was described recently (22, 27) . Plasmid pPVRdl/CD4, encoding a hybrid PVR/CD4 receptor of 398 amino acids, was constructed from pTMPVR and pSV7d, the latter containing CD4 cDNA (provided by Dan Littman). Plasmid pTMPVR contains two silent mutations at nucleotide 663 and nucleotide 946 harboring restriction sites for NheI and HpaI at the C-terminal ends of domain 1 (NheI) and domain 2 (HpaI), respectively. These mutations allowed us to join the immunoglobulinlike domains of PVR and CD4 at the desired boundaries. Plasmid pTMPVR was digested with NheI and HpaI, and a NheI-HpaI fragment of pSV7d was inserted, leading to an in-frame fusion of the coding sequence of domain 1 of PVR (amino acids 1 to 143) to the sequence coding for amino acids 214 to 468 of CD4 (Fig. 1A) .
All constructs were expressed in the eukaryotic expression vector pTM1 (20) , which is under the control of the bacteriophage T7 promoter, by transfection of mouse MOP8 cells through electroporation. Thirty minutes prior to transfection, the cells were infected with a recombinant vaccinia virus (vTF7-3 [7] ) at a multiplicity of infection of 5 to provide T7 RNA polymerase in the cytoplasm. surface expression of these molecules (Fig. 2) . After being stained with poliovirus receptor-specific monoclonal antibody D171 (21), the expression of the putative receptor molecules was found to be proportional to the relative fluorescence intensity. All three receptor constructs were expressed in similar amounts on the surfaces of transfected cells. In order to determine the specific attachment of poliovirus to these cells, binding assays with 35S-labeled poliovirus were conducted. As depicted in Fig. 3 , a significant increase in binding of poliovirus was detected on receptor-transfected mouse cells. Therefore, fusion of the PVR binding domain to the CD4 molecule (PVRdl/CD4) maintained the overall structure of the binding site for poliovirus. Virus binding to both mutant receptors (PVRdl/ CD4 and PVRdl), however, did not exceed 20 to 30% of binding to the wild-type receptor. As discussed below, domains 2 and 3 of PVR may improve presentation of the poliovirus-binding domain. We then addressed the question of whether the PVRdl/CD4 molecule is able to mediate uptake of poliovirus into cells. Poliovirus infections were carried out 12 to 16 h after transfection of receptor DNA, as described previously (22) . As shown by one-step growth curves (Fig. 4) , poliovirus replicated in PVRdl/CD4 receptor transfectants. The yield of infectious virus 4 h postinfection was significantly lower in cells expressing the chimeric PVRd1/CD4 receptor. However, later in infection, similar virus titers were recovered from both cell populations expressing the truncated receptors PVRdl and PVRdl/CD4.
The observation that the PVR/CD4 chimeric receptor molecule, as well as the PVR/ICAM-1 chimera described before (22) , is a functional viral receptor is interesting for several reasons. First, it confirms that the N-terminal domain of PVR is the virus-binding domain and that it is sufficient to confer receptor function for poliovirus infection (22) . The N-terminal domains of the HIV receptor (CD4 [1, 11, 19] ) and the rhinovirus receptor (ICAM-1 [12, 23] ing of the naked poliovirus can be safely assumed to differ from that of the enveloped HIV, and that may be underscored by the data presented here.
The mechanism by which the poliovirus genome is released into the cytoplasm is poorly understood. The first step in uncoating is thought to be the receptor-mediated formation of A particles (particles lacking VP4) that, by means of their newly acquired hydrophobic properties, can interact with membranes (6, 13) . Available evidence has been interpreted to mean that poliovirions, or A particles, enter cellular endosomes, whose ATP-dependent acidification is obligatory for infection (for a review, see reference 16). CD4 molecules undergo endocytosis (14) , and thus it is conceivable that the PVRdl/CD4 chimeric receptor could transport poliovirus into endosomes via coated pits. On the other hand, the validity of the model of endocytosis for poliovirus uptake has been challenged recently (8) . CD4-dependent HIV infection does not involve endocytosis (14) . By analogy with HIV infection, it is possible that the function of the PVRdl/CD4 chimeric receptor is to position the virion in the vicinity of the plasma membrane and to convert it to an A particle that, in turn, will promptly interact with the membrane to initiate penetration. Such a mechanism, which bypasses endocytosis, could also apply to PVR-mediated poliovirus infection.
